ABUS Arbutus Biopharma Corp.

Arbutus to Report Fourth Quarter and Year-End 2019 Financial Results

Arbutus to Report Fourth Quarter and Year-End 2019 Financial Results

WARMINSTER, Pa., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its fourth quarter and Year-End 2019 financial results, conference call and webcast for Thursday, March 5, 2020.  The schedule for the press release and conference call/webcast are as follows:

•Q4 2019 Press Release:March 5, 2020 at 7:30 a.m. ET
•Q4 2019 Conference Call:March 5, 2020 at 8:45 a.m. ET
•Domestic Dial-In Number:(866) 393-1607
•International Dial-In Number:(914) 495-8556
•Conference ID Number:5084457

A live webcast of the conference call can be accessed through the Investors section of Arbutus' website at .

An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling (855) 859-2056 or (404) 537-3406, and reference conference ID 5084457.

About Arbutus

Arbutus Biopharma Corporation is a publicly-traded (Nasdaq: ABUS) biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B (HBV) infection. Arbutus is developing multiple drug candidates, each of which have the potential to improve upon the standard of care and contribute to a curative combination regimen. For more information, visit .

Contact Information

Investors and Media

William H. Collier

President and CEO

Phone: 604-419-3200

Email:

Pam Murphy

Investor Relations Consultant

Phone: 604-419-3200

Email:

 

EN
27/02/2020

Underlying

ABUSArbutus Biopharma Corp.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Arbutus Biopharma Corp.

 PRESS RELEASE
Free
ABUS Arbutus Biophar...

Arbutus Reports Third Quarter 2025 Financial Results and Provides Corp...

Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update Strong financial position with cash, cash equivalents and marketable securities of $93.7M  Moderna litigation U.S. trial scheduled for March 2026;Favorable claim construction ruling in Pfizer-BioNTech litigation issued in September 2025  Additional analysis of imdusiran (AB-729) clinical data shows:-46% of Phase 2a patients met criteria to discontinue all treatment-94% of long-term follow-up patients remain off all treatment for up to 2+ years-100% of HBV DNA positive patients in Phase 1b achieved HBV DNA lev...

November 13, 2025 1 EN
 PRESS RELEASE
Free
ABUS Arbutus Biophar...

Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - ...

Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025 Multiple abstracts accepted featuring imdusiran clinical data – highlighting progress toward a potential functional cure for chronic hepatitis B virus AB-101 clinical data abstract recognized as a Poster of Distinction WARMINSTER, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that three abstracts featuring imdusiran data and one abstract fe...

October 7, 2025 1 EN
 PRESS RELEASE
Free
ABUS Arbutus Biophar...

Arbutus Reports Second Quarter 2025 Financial Results and Provides Cor...

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran Dr. Roger Sawhney joins the Arbutus Board of Directors following resignation of Anuj Hasija Dr. Harry Janssen joins the Arbutus Scientific Advisory Board Strong financial position with cash, cash equivalents and marketable securities of $98.1M WARMINSTER, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-s...

August 6, 2025 1 EN
 PRESS RELEASE
Free
ABUS Arbutus Biophar...

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Sci...

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Greater China Drs. Jordan Feld, Ed Gane, Anna Lok, Mark Sulkowski and Man-Fung Yuen join Arbutus Scientific Advisory Board WARMINSTER, Pa., June 25, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that it has reacquired China ri...

June 25, 2025 1 EN
 PRESS RELEASE
Free
ABUS Arbutus Biophar...

Arbutus Reports First Quarter 2025 Financial Results and Provides Corp...

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B (cHBV) to date, including 2 patients who received no interferon AB-101, oral small-molecule PD-L1 inhibitor, shown generally safe and well-tolerated with evidence of high receptor occupancy in Phase 1a/1b Andrew J. Sung joins Arbutus as General Counsel, bringing more than $28 billion in life sciences deal experience Strong financial position with cash, cash equivalents and marketable securities of $113M WARMINSTER, Pa...

May 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch